Cases & Deals

  • Home
  • Practices
  • Exegenesis Bio establishes global patent portfolio related to AAV-based gene therapies

Share

Exegenesis Bio establishes global patent portfolio related to AAV-based gene therapies

January 2023

Client(s) Exegenesis Bio

Jones Day is representing Exegenesis Bio in connection with the establishment of global patent portfolios related to AAV-based gene therapies for treating central nervous system (CNS), ocular and liver related diseases.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.